Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients : vimarsana.com

Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients

/PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced the publication of findings from a retrospective chart review of...

Related Keywords

United States , Dublin , Ireland , San Francisco , California , New York , Americans , American , Derek Belz , Mary Mcgowan , Data Sciences , Green Room Communications , Mallinckrodt Pharmaceuticals , American College Of Chest Physicians , American Thoracic Society Annual International Conference , Foundation For Sarcoidosis Research , American Medical Association Physician Masterfile , Drug Administration , Acthar Gel , African Americans , African American , Clinical Risk , Thoracic Society Annual International Conference , Therapeutic Advances , Respiratory Disease , Important Safety Information , George Wan , Vice President , Evidence Generation , Chief Executive Officer , Sarcoidosis Research , Physician Assessment , Prescribing Information , Important Safety , Specialty Brands , Specialty Generics , Annual Report , Non African Americans , Symptomatic Sarcoidosis , Patient Medical , Ther Clin Risk , Corticotropin Injection , Advanced Symptomatic Sarcoidosis , Retrospective Analysis , Ther Adv Res , Humana Press , Sarcoidosis Epidemiology , American College , Accessed February , Clinical Course , Large White , Black Cohort , Sarcoidosis Vasc Diffuse Lung , Mallinckrodt Plc ,